NEVVI Medicare utilization intelligence

← back

LAPINSKY, EVANMD NPI 1134486046 Clinician

Hematology-Oncology · NEWARK, DE

Specialty Hematology-Oncology — from billed Medicare claims
Trained JEFFERSON MEDICAL COLLEGE OF THOMAS JEFFERSON UNIVERSITY — medical school, self-reported to CMS
In practice about 7 years since medical school (class of 2019, self-reported to CMS)
Location NEWARK, DE · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 45 codes billed · 61,748 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20202026
MEDICAL ONCOLOGY HEMATOLOGY CONSULTANTS PA
2020–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2022-09

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9263 Injection, oxaliplatin, 0.5 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9271 Injection, pembrolizumab, 1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J0640 Injection, leucovorin calcium, per 50 mg
J1437 Injection, ferric derisomaltose, 10 mg
J9190 Injection, fluorouracil, 500 mg
J9206 Injection, irinotecan, 20 mg
J2469 Injection, palonosetron hcl, 25 mcg
J1626 Injection, granisetron hydrochloride, 100 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96375 Injection of additional new drug or substance into vein
J9045 Injection, carboplatin, 50 mg
J3480 Injection, potassium chloride, per 2 meq
J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96415 Administration of chemotherapy into vein, each additional hour
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96372 Injection of drug or substance under skin or into muscle
96417 Administration of additional new drug or substance into vein, 1 hour or less
96411 Administration of additional new drug or substance into vein using push technique
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
J2405 Injection, ondansetron hydrochloride, per 1 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J3489 Injection, zoledronic acid, 1 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J3475 Injection, magnesium sulfate, per 500 mg
J7030 Infusion, normal saline solution , 1000 cc
96360 Infusion into a vein for hydration, 31-60 minutes
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
J1200 Injection, diphenhydramine hcl, up to 50 mg
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96523 Irrigation of implanted venous access drug delivery device
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
J3490 Unclassified drugs
36591 Collection of blood sample from implanted device

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.